Back

Effects of intensive blood pressure control in patients with cardiovascular-kidney-metabolic syndrome:a post hoc analysis from ESPRIT

31 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Cardiovascular risk detection in primary care: blood pressure, adiposity, and preventive strategies Cardiovascular Disease in Primary Care ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Yinchu Li

(China)

5 More presentations in this session

Presentation thumbnail
High-risk psoriasis patients are not consistently escalated to cardiovascular specialist care
Ms T. Mai (FR)
Abstract
Presentation thumbnail
Burden of cardiopulmonary events following diagnosis of COPD; a nationwide linked primary care, secondary care and death registry study
Professor C. Gale (Leeds, GB)
Abstract
Presentation thumbnail
Effect of homocysteine on the outcomes of intensive blood pressure control: a post hoc analysis of the ESPRIT trial
Miss Y. Li (CN)
Abstract
Presentation thumbnail
Digital phenotyping and additive multimorbidity scoring to operationalise very-high-risk secondary prevention in primary care
Professor R. Varma (Tbilisi, GE)
Abstract
Presentation thumbnail
Association between Chinese Visceral Adiposity Index and cardiovascular events in patients with cardiovascular kidney-metabolic syndrome stages 0–3: a longitudinal analysis based on CHARLS
Doctor Y. Chen (Anzhen, CN)
Abstract

Access the full session

Session thumbnail
Cardiovascular risk detection in primary care: blood pressure, adiposity, and preventive strategies

The Event

Event poster

ESC Congress 2026

31 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Design of a multicenter, open-label, randomized controlled trial: effects of intensive systolic blood pressure lowering treatment in reducing risk of vascular events (ESPRIT)
2 September 2019
thumbnail
Congress Session
Cardio-renal-metabolic conundrum in heart failure
19 May 2025
thumbnail
ESC Journals
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial
29 August 2020
thumbnail
Congress Presentation
Long-term outcomes after renal denervation in the two defined ESC guideline-recommended patient groups: an analysis from the Global SYMPLICITY Registry DEFINE
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources